ClinicalTrials.gg
Not yet recruitingNCT07502222Updated Mar 30, 2026

A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Moderate-to-severe Atopic Dermatitis

A Phase 2 interventional study of AK139 and placebo and AK139 in Moderate-to-Severe Atopic Dermatitis, sponsored by Akeso. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by Akeso · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK139 in the treatment of patients with moderate-to-severe atopic dermatitis.

02

Conditions studied

  • Moderate-to-Severe Atopic Dermatitis

Browse trials for

03

In context

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

This study's planned enrollment of 168 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.

Browse Dermatitis, Atopic studies →

Lead sponsor

Akeso is the lead sponsor of 157 studies on the registry; 67 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to understand the study and voluntarily sign the ICF.
  2. Atopic dermatitis (AD) diagnosed at least 6 months before screening.
  3. Eczema Area and Severity Index (EASI) score ≥16, Investigator's Global Assessment (IGA) score ≥3, and Body surface area (BSA) involvement ≥10% at both screening and baseline.
  4. A weekly average of daily Peak Pruritus Numerical Rating Scale (P-NRS) score ≥4 at baseline.
  5. Inadequate response or intolerance to prior topical therapy for AD.
  6. The patients agree to use highly effective methods from the moment of signing of the ICF to 90 days after the last dose of the product.

Exclusion criteria

Exclusion Criteria:

  1. Acute onset of AD within the first 4 weeks of randomization.
  2. Received systemic , /immunomodulatory drugs, phototherapy or other systemic therapies used for AD within the 4 weeks before randomization.
  3. Received treatment with other clinical research drugs (non-biological agents) within the first 4 weeks or 5 half-lives of randomization (whichever is longer)
  4. Received or planned to receive treatment within the 12 weeks before randomization or during the study period.
  5. Received allergen specific immunotherapy within the 12 weeks before randomization.
  6. Have a history of allergies to any component of AK139 and/or severe allergic reactions to monoclonal antibodies.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
168 participants (estimated)

Study arms

  • Experimental
    Part 1: AK139 regimen 1

    Biological: AK139 and placebo

  • Experimental
    Part 1: AK139 regimen 2

    Biological: AK139

  • Experimental
    Part 1: AK139 regimen 3

    Biological: AK139 and placebo

  • Experimental
    Part 1: AK139 regimen 4

    Biological: AK139

  • Experimental
    Part 2: AK139 regimen 5

    Biological: AK139 and placebo

  • Experimental
    Part 2: AK139 regimen 6

    Biological: AK139 and placebo

  • Placebo comparator
    Part 2: Placebo

    Biological: Placebo

Interventions

  • BiologicalAK139 and placebo

    AK139 plus placebo regimen 1-subcutaneous injection.

  • BiologicalAK139

    AK139 regimen 2-subcutaneous injection.

  • BiologicalAK139 and placebo

    AK139 plus placebo regimen 3-subcutaneous injection.

  • BiologicalAK139

    AK139 regimen 4-subcutaneous injection.

  • BiologicalAK139 and placebo

    AK139 plus placebo regimen 5-subcutaneous injection.

  • BiologicalAK139 and placebo

    AK139 plus placebo regimen 6-subcutaneous injection.

  • BiologicalPlacebo

    Placebo-subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Incidence and severity grading of Adverse Events (AE)(applicable to Part 1)

    Time frame: Up to Week 16 (applicable to the Q4W dosing group); Up to Week 8 (applicable to the Q2W dosing group).

  2. Percentage of patients who achieved Eczema Area and Severity Index (EASI)-75 (applicable to Part 2)

    Time frame: at week 16

Secondary outcomes

  1. Percentage of patients achieving an IGA score of 0 or 1 at each visit, with a reduction of ≥2 points from baseline

    Time frame: Up to Week 24

  2. Percentage change in affected Body Surface Area (BSA)

    Time frame: Up to week 24

  3. Percentage change of Peak Pruritus Numerical Rating Scale (P-NRS) scores

    Time frame: Up to week 24

  4. Percentage changes in the Dermatology Life Quality Index (DLQI) score

    Time frame: Up to week 24

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Nov 2027, 19 months later.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's planned 19 months is above that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2026
First posted
Mar 30, 2026
StartEst.
Apr 7, 2026
Primary completionEst.
Nov 2027
CompletionEst.
Jan 10, 2028
Last update
Mar 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07502222
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Mar 30, 2026
Start date
Apr 7, 2026 (estimated)
Primary completion
Nov 2027 (estimated)
Completion
Jan 10, 2028 (estimated)
Last update
Mar 30, 2026

Study contacts

Guoqin Wang
Contact
global.trials@akesobio.com
+86 (0760) 8987 3999

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AK139

Start the discussion